Year: 2017
Type: editorial
Abstract: Patients with severe asthma generally benefit from consultations with an asthma specialist to optimise their management, which may include the potential initiation of biologic agents that have made a breakthrough in the treatment of severe disease. Physicians need care pathways to select a biologic in type 2 severe asthma (omalizumab, mepolizumab, reslizumab) <http://ow.ly/pygw30gB7Bv>
Source: European Respiratory Journal
Institutions: Inserm, Université de Versailles Saint-Quentin-en-Yvelines, Vieillissement et Maladies Chroniques. Approches Epidémiologiques et de santé publique, Ghent University Hospital, University Medical Center of the Johannes Gutenberg University Mainz, University of Wisconsin–Madison, Universidade Federal da Bahia, NIHR Southampton Respiratory Biomedical Research Unit, University of Southampton, Universitat Autònoma de Barcelona, Corporació Sanitària Parc Taulí, Baylor College of Medicine, American Lung Association, Université Paris-Sud, Bicêtre Hospital, Royal Brompton Hospital, Boston Children's Hospital, Harvard University, Stiftung Charité, Charité – Universitätsmedizin Berlin, National Jewish Health
Language: English
Subfield: Physiology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2775249353